Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Is open innovation the way forward for big pharma?

Nature Reviews Drug Discovery volume 9, pages 87–88 (2010)Cite this article

Subjects

Abstract

The current, fully integrated business model of large pharmaceutical companies is increasingly considered to be unsustainable, and so new approaches that engage large and small companies, governments and academic institutions are needed. Could 'open innovation' models that have proved successful in other sectors be fruitfully adopted by the pharmaceutical industry?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chesborough, H. W. Open Innovation: the New Imperative for Creating and Profiting from Technology 1–272 (Harvard Business School, Boston, Masschusetts, 2003).

    Google Scholar 

  2. Tapscott, D. & Williams, A. D. Wikinomics: How Mass Collaboration Changes Everything 1–320 (Portfolio, New York, 2006).

    Google Scholar 

  3. Munos, B. Can open-source R&D reinvigorate drug research? Nature Rev. Drug Discov. 5, 723–729 (2006).

    Article  CAS  Google Scholar 

  4. Huston, L. & Sakkab, N. Connect and Develop: Inside Procter & Gamble's new model for innovation. Harv. Bus. Rev. 84, 58–66 (2006).

    Google Scholar 

  5. Barnes, M. R. et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nature Rev. Drug Discov. 8, 701–708 (2009).

    Article  CAS  Google Scholar 

  6. Hughes, B. Harnessing open innovation. Nature Rev. Drug Discov. 8, 344–345 (2009).

    Article  Google Scholar 

  7. Alexy, O. et al. Does IP strategy have to cripple open innovation?' MIT Sloane Management Rev. 51, 73–77 (2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jackie Hunter is Senior Vice President of Science Environment Development at GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, UK.,

    Jackie Hunter

  2. Susie Stephens is Director of Biomedical Informatics at Johnson & Johnson Pharmaceutical Research & Development, 145 King of Prussia Road, Radnor, Pennsylvania 19087, USA. The views expressed herein are not necessarily those of the employer of S.S.,

    Susie Stephens

Authors
  1. Jackie Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susie Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jackie Hunter.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hunter, J., Stephens, S. Is open innovation the way forward for big pharma?. Nat Rev Drug Discov 9, 87–88 (2010). https://doi.org/10.1038/nrd3099

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3099

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research